DiaSorin SpA receives Investment Bank Analyst Rating Update
By Peter Nurse Investing.com - U.S. stocks are seen edging lower at the open Monday, retreating from last week’s record levels ahead of the start of the first-quarter reporting...
By Geoffrey Smith Investing.com -- Jerome Powell predicts a surge in hiring and economic growth - but still wants you to wear a mask and keep socially distanced. India's pandemic...
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.
|Average||122.733 (+20.268% Upside)|
|No. of Analysts||12|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|